Trials / Completed
CompletedNCT00111852
Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)
A Prospective, Randomized, Double-blind, Placebo-controlled, Single Bolus, Multinational, Multi-center, Parallel Group, Dose-ranging Study of Desmoteplase (INN) in the Indication of Acute Stroke
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 193 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate desmoteplase (which is a manufactured protein derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of blood through one (or more) of the blood vessels supplying the brain, thereby reopening the blocked blood vessel and allowing blood to flow again in individuals suffering from ischemic stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desmoteplase | Desmoteplase 90 mcg/kg, intravenous administration. |
| DRUG | Desmoteplase | Desmoteplase 125 mcg/kg, intravenous administration. |
| DRUG | Placebo | Dose-Match Placebo, intravenous administration. |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2007-03-01
- First posted
- 2005-05-27
- Last updated
- 2012-03-20
Locations
44 sites across 8 countries: United States, Australia, Austria, Canada, Finland, Germany, Netherlands, Spain
Source: ClinicalTrials.gov record NCT00111852. Inclusion in this directory is not an endorsement.